Abstract Number: 725 • 2016 ACR/ARHP Annual Meeting
Long-Term Anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in the Sacroiliac Joints in Patients with Non-Radiographic Axial Spa: Six-Year Results of the Esther Trial
Background/Purpose: Data from observational studies suggests a 10-12% biannual rate of progression from non-radiographic axial SpA (nr-axSpA) to ankylosing spondylitis (AS)1 in patients not treated…Abstract Number: 2696 • 2016 ACR/ARHP Annual Meeting
Identification of a Potential Commensal Immunologic Target in Enthesitis-Related Arthritis
Identification of a Potential Commensal Immunologic Target in Enthesitis-related Arthritis Background/Purpose: Research in inflammatory bowel disease (IBD) has identified commensal organisms that stimulate humoral and…Abstract Number: 3039 • 2016 ACR/ARHP Annual Meeting
Anti-IL-17A, but Not Anti-TNF, Can Halt Pathological New Bone Formation in Experimental Spondyloarthritis
Background/Purpose: Secukinumab, a monocloncal antibody to IL-17A, suppresses signs and symptoms as well as inflammation in ankylosing spondylitis and psoriatic arthritis, and inhibits bone and…Abstract Number: 684 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups
Background/Purpose: The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being. A few studies have assessed…Abstract Number: 2842 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Background/Purpose: Several studies have demonstrated that Tumor Necrosis Factor Inhibitors (TNFi) are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). However, few investigations have directly compared ankylosing…Abstract Number: 2875 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Background/Purpose: The use of TNF inhibitors (TNFIs) has led to efficient control of the signs and symptoms of SpA and rheumatoid arthritis (RA), and significantly…Abstract Number: 3008 • 2014 ACR/ARHP Annual Meeting
High Prevalence of Subclinical Ultrasonographic Enthesopathy and Synovitis in Patients with Inflammatory Bowel Disease without Clinical Signs or Symptoms of Spondyloarthritis
Background/Purpose Musculoskeletal manifestations as peripheral arthritis, axial disease and enthesitis are present in 10-62% of Inflammatory Bowel Disease (IBD) patients. Ultrasonography is more sensitive than…Abstract Number: 2983 • 2014 ACR/ARHP Annual Meeting
Infliximab Added to Naproxen Does Not Increase Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints and of the Spine As Compared to Naproxen Alone in Early Axial Spondyloarthritis
Background/Purpose: Fatty lesions of the bone marrow in the axial skeleton (sacroiliac joints – SIJ, and spine) on magnetic resonance imaging (MRI) are considered nowadays…Abstract Number: 2596 • 2014 ACR/ARHP Annual Meeting
Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort
Background/Purpose: Based on the predominant manifestation of the disease, the ASAS classification criteria for spondyloarthritis (SpA) distinguish two clinical forms: •Axial SpA, including non-radiographic SpA…Abstract Number: 2593 • 2014 ACR/ARHP Annual Meeting
Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort
Background/Purpose In cross-sectional studies it has been demonstrated that non-radiographic axial spondyloarthritis (nr-axSpA) does not differ from ankylosing spondylitis (AS) with respect to clinical signs…Abstract Number: 2592 • 2014 ACR/ARHP Annual Meeting
Assessment of Spondyloarthritis International Society Endorsed Recommendations for Early Referral of Patients Suspected for Axial Spondyloarthritis
Background/Purpose There is a substantial gap of 5 to 8 years between the onset of symptoms (usually back pain) and the diagnosis of axial spondyloarthritis…Abstract Number: 2557 • 2014 ACR/ARHP Annual Meeting
Are We over-Treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), and even in early forms, patients symptoms may lead to…Abstract Number: 2573 • 2014 ACR/ARHP Annual Meeting
Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Background/Purpose The ASAS Health Index (ASAS HI) is a disease-specific questionnaire aiming at measurement of health in patients with spondyloarthritis (SpA) which has been developed…Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…Abstract Number: 541 • 2014 ACR/ARHP Annual Meeting
Collagen II Neo-Epitopes in Spondyloarthritis.
Background/Purpose Spondyloarthritis (SpA) is characterized by aseptic inflammation of the axial skeleton which may ultimately lead to irreversible deformities due to bony ankylosis. Occasionally, peripheral…
ACR Meeting Abstracts